T1	Participants 114 160	HIV-infected pregnant women and their newborns
T2	Participants 382 548	the first 28 maternal-infant pairs enrolled in a randomized, intravenous immunoglobulin (IVIG)-controlled trial of HIVIG maternal-infant HIV transmission prophylaxis.
